Experimental antidote reverses effects of dabigatran in trial

11/18/2013 | Reuters

Scientists have developed an agent that reverses the anticoagulation effects of dabigatran, a blood-thinning drug developed by Boehringer Ingelheim. The antidote is a fragment of a monoclonal antibody that helps eliminate the drug from the bloodstream. Complete reversal of the drug's anticoagulation effect was seen among healthy volunteers who received the antidote through five-minute intravenous infusions after four days of taking dabigatran.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT